Human-Relevant Non-Animal Methodologies (NAMs)
Specialised Models Series: **Neurological & Psychiatric**

Neurological / Brain / CNS Models

Reference 3.1 in Full Scope Roadmap

Version 1.0 | June 2026 Edition
Compiled for the Alliance for Cruelty Free Science by Georgina Rednall
Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and Principal Investigators

Legal & Scientific Imperative for Universities

Section 2A of the *Animals (Scientific Procedures) Act 1986* imposes a statutory duty on the Secretary of State to ensure compliance with the principles of replacement, reduction, and refinement. The principle of replacement requires that, wherever a scientifically satisfactory method or testing strategy not entailing the use of protected animals is available, it must be used to replace the use of a regulated procedure.

Traditional neurobiology workflows rely heavily on legacy *in vivo* models—such as transgenic rodent models of Alzheimer's or Parkinson's disease, and non-human primates for cognitive or neurodegenerative studies. These legacy platforms suffer from severe translational limitations due to fundamental species differences. These limitations are evident in the following critical disparities:

- **Glial Cell Phenotype & Function:** Human glial cells—particularly astrocytes and microglia—exhibit distinct morphological and functional properties compared to rodent counterparts. These differences are crucial for neuroinflammation and synaptic regulation, and their misrepresentation leads to failures in neuroprotective drug testing.

- **Protein Isoform & Pathological Mismatch:** Many neurodegenerative diseases are driven by human-restricted protein isoforms (e.g., specific tau or amyloid-β configurations). Animal models frequently overexpress mutated human proteins that do not mimic the natural, progressive pathogenesis observed in human clinical cases.

- **Blood-Brain Barrier (BBB) Architecture:** The human BBB is exceptionally complex, governed by unique interactions between human endothelial cells, pericytes, and astrocytes. Rodent BBB models fail to capture the human-specific transport mechanisms and permeability dynamics required for successful CNS drug delivery.

- **Severity of Neurological Assessment:** Models involving induced brain lesions, chronic neurodegeneration, or invasive stereotactic procedures cause significant animal suffering, cognitive distress, and physical morbidity, providing a major ethical and regulatory impetus to prioritise replacement.

Accelerating the adoption of human-relevant Non-Animal Methodologies (NAMs)—such as microfluidic blood-brain barrier chips, patient-derived brain organoids, and predictive computational networks of neurotoxicity—is therefore both a scientific imperative to solve the clinical translation crisis and a legal mandate for UK universities.

Landmark Regulatory & Scientific Momentum

Significant progress has been made in the development and application of human-relevant neurological and CNS NAMs:

Human Neurovascular Unit (NVU) & BBB-on-Chip: Faithfully recapitulates the selective permeability, shear stress dynamics, and multi-lineage cellular interactions (endothelial cells, pericytes, and astrocytes) of the human blood-brain barrier.

Brain Organoids & Assembled "Assembloids": Utilise induced pluripotent stem cells (iPSCs) to generate self-organising 3D brain tissue that mimics human cortical layering, regional brain architecture, and functional synaptic network activity.

In Silico Neurocomputational Modelling: Leverages structural molecular biology and machine learning to map neurotoxic pathways, forecast blood-brain barrier penetration mechanics, and simulate network-level synaptic dysfunction.

Core Specialised CNS Platforms



Figure 1: Core Specialised Neurological Platforms — Microfluidic blood-brain barrier and neurovascular unit chip capturing endothelial-astrocyte cross-talk under fluid flow *(left)*, regionalised 3D brain organoid/assembloid system displaying cortical layering and functional synaptic firing patterns *(centre)*, and a high-throughput microelectrode array (MEA) microplate tracking multi-lineage human neuronal network connectivity *(right)*.

Table 1: Biological & Tissue-Engineered (In Vitro) Platforms

This table captures the structural, physical, and cellular models that recreate human brain architecture, cellular barriers, and functional neural networks.

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
Neurovascular Unit (NVU) / BBB-on-Chip	Microfluidic platforms hosting human primary or iPSC-derived brain endothelial cells, pericytes, and astrocytes separated by a porous membrane under physiological shear stress.	Evaluating blood-brain barrier permeability, receptor-mediated transcytosis of therapeutics, and localised neurovascular inflammatory responses.	Provides a high-fidelity human alternative to legacy rodent tail-vein injection and pharmacokinetic penetration assays.
Patient-Derived 3D Brain Organoids	iPSC-derived self-organizing cortical or midbrain tissue models that recreate human-specific cell-type ratios, structural layering, and early neural pathology.	Modeling neurodegenerative progression (e.g., Alzheimer's tau pathology, Parkinson's α-synuclein aggregation), viral neurotropism, and early neurodevelopment.	Replaces transgenic rodent lines that fail to accurately capture human-restricted protein misfolding, neurodegeneration kinetics, or cognitive pathology.
High-Throughput Microelectrode Arrays (MEAs)	Human iPSC-derived neurons and glia cultured directly over multi-well microplates embedded with multi-channel microelectrodes.	Real-time monitoring of functional network connectivity, synaptic firing, seizure-induction (epileptiform) assays, and acute neurotoxicity screening.	Shifts functional neural screening into automated, cell-based pipelines, bypassing invasive rodent electrophysiology and stereotaxic surgeries.

Cross-Cutting & Enabling Platforms for Neurological Research

These platforms support multiple neurological, neurodegenerative, and psychiatric research areas and are widely applicable across various blood-brain barrier transport mechanics, neuro-inflammatory screening pipelines, and targeted cell-based or small-molecule therapies. While specialised models focus on localised organ or tissue niches (such as cortical layers or localised neurovascular regions), these enabling platforms are essential for validating high-maturity NAMs and ensuring they meet the high standards required for regulatory-accepted, "fit-for-purpose" research.



Figure 2: Cross-Cutting & Enabling Platforms for Neurological Research — AlphaFold-driven structural modelling of misfolded neural proteins and receptor-targeting therapeutic candidates (left), multi-scale computational digital twins simulating neural circuit degeneration over time *(centre)*, and quantitative Adverse Outcome Pathway (qAOP) networks mapping molecular initiation events to functional neurotoxicity phenotypes *(right)*.

Table 2: Genetic, Computational & Framework-Driven Platforms

This table captures the cross-cutting technologies—including machine learning, in silico simulation, and structured pathways—used to design CNS therapies and predict human neurofunctional responses.

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
AlphaFold & AI-Driven Structural Modelling	Computational protein-structure prediction tools used to map 3D conformations of human-specific receptor matrices, ion channels, and misfolded protein aggregates.	Modelling specific tau configurations, amyloid-β plaques, and α-synuclein binding sites; optimizing blood-brain barrier transporter target configurations.	Replaces animal-based antibody generation and structural extraction methods that rely on harvesting animal brain tissues.
In Silico Neural Circuit Digital Twins	Mathematical and kinetic computational models that simulate whole-brain or regional neural circuit signaling and synaptic decay over time.	Forecasting long-term disease progression, network-level drug effects, and optimizing clinical trial patient selection criteria.	Holistic systems biology tool; ideal for guiding experimental parameters and replacing multi-year longitudinal non-human primate studies.
qAOP-Integrated Neurotoxicity Screeners	Quantitative Adverse Outcome Pathway (qAOP) networks linking molecular initiation events (e.g., receptor binding) to structural neurodegeneration.	Regulatory-grade safety screening for developmental neurotoxicity (DNT), environmental toxicity profiling, and drug-induced seizures.	Aligns perfectly with Home Office / ASRU standards for regulatory acceptance and "fit-for-purpose" safety profiling.

Regulatory Software & Strategy Frameworks

- Regulatory acceptance of NAMs—referred to as "fit-for-purpose qualification"—is not a one-size-fits-all process. Researchers should utilise the following frameworks to ensure their computational and biological strategies align with the *Animals (Scientific Procedures) Act 1986* and industry best practices:
- **Context of Use (COU) Documentation:** Before deploying models, clearly define the specific scientific question the model is intended to address. This is critical for demonstrating that the NAM is reliable and suitable for its intended regulatory purpose.
- **Technical Characterisation:** Maintain comprehensive Standard Operating Procedures (SOPs) and study plans for both the biological NAM and any software used to analyse its output. This transparency is vital for successful project licence applications.
- **Early Regulatory Engagement:** Leverage institutional or external regulatory support to track "fit-for-purpose" milestones. Early engagement with the Home Office/ASRU is strongly encouraged to test the acceptability of a computational or NAM-based approach before full project submission.
- **Weight-of-Evidence (WoE) Frameworks:** Use integrated digital dashboards to aggregate data from both *in vitro* (NAM) and *in silico* (computational) sources. Building a strong "weight-of-evidence" argument is the most effective way to strengthen Replacement justifications when moving away from traditional animal models.

Skills • Training, and Capacity Building

Successful adoption of high-maturity Non-Animal Methodologies (NAMs) requires a strategic shift in workforce development. To ensure the long-term success of the platforms outlined in this series, universities should prioritise the following training initiatives to build institutional capacity:

- **Integrated Neurobiology & Microengineering:** Training programmes should bridge the gap between bench-top cellular biology, fluidic microengineering, and complex electrophysiology data analysis. Researchers require dual proficiency in maintaining long-term fluidic barrier models and leveraging the computational pipelines necessary to interpret high-density microelectrode array data.
- **Regulatory Competency:** Staff should receive formal training on "Fit-for-Purpose" qualification and the specific regulatory expectations of the Home Office/ASRU. This includes understanding how to document evidence for the 3Rs within formal project licence applications to ensure they meet legal standards.
- **Technological Literacy:** Skills in microfluidic device troubleshooting, primary stem-cell tissue differentiation, brain organoid maintenance, and AI-driven structural computational modelling are increasingly critical for modern neurobiology research. Universities should facilitate internal workshops or establish external partnerships to provide PhD students and postdoctoral fellows with hands-on experience in these specialised tools.
- **Ethics & Translation:** Education should focus on the scientific imperative of human-relevant research, emphasising why NAMs provide more predictive insights for clinical outcomes than traditional rodent or non-human primate models. This fosters a culture of excellence and ethical research design that is fully aligned with modern international standards.

Table 3: Skills • Training and Capacity Building

Capability Domain	**Focus Area**	**Impact on 3Rs/Replacement**
Technical	Brain organoid culture & BBB-on-chip assembly	Direct replacement of transgenic rodent/primate models
Bioinformatics	Human-specific neuro-transcriptomic analysis	Bypasses animal-based brain tissue sampling
Regulatory	ASPA 1986 Compliance & AWERB	Facilitates faster approval for non-animal research
Computational	Neuro-toxicity & drug-transport modelling	Eliminates invasive animal stereotactic/ behavioural studies

Strategic Note: This investment in human expertise is a key component of a robust, future-proof institutional roadmap, demonstrating to regulators that the institution is committed to the safe and effective operation of high-maturity NAMs.

Clinical Translation Case Studies

Case Study 1: Human Blood-Brain Barrier-on-Chip Correcting Rodent Transport Anomalies

- **Background:** A major pharmaceutical candidate designed to clear amyloid plaques showed high brain penetration in mouse models via receptor-mediated transport. However, it completely failed in early human clinical trials due to zero blood-brain barrier penetration, costing millions in wasted development.
- **The Paradigm Shift:** A university neurobiology lab re-evaluated the failed therapeutic using a microfluidic human neurovascular unit chip. The human-relevant platform correctly predicted the clinical failure, demonstrating that the specific target transporter is expressed differently in human brain endothelium compared to rodents.
- **The Methodology:** Researchers used the microfluidic platform to measure real-time human endothelial permeability, receptor binding dynamics, and astrocyte-mediated transport kinetics. The human chip accurately mirrored the clinical zero-penetration data, proving that animal transport profiles were false-positive indicators.
- **University & Legal Takeaway:** These results offer compelling non-animal evidence to support Project Licence applications, illustrating a clear methodology for replacing animal pharmacokinetic models under ASPA 1986 requirements.

Case Study 2: iPSC-Derived Cortical Organoids Validating Neurodegenerative Targets

- **Background:** Developing a novel small-molecule therapeutic to halt tau hyperphosphorylation in Alzheimer's disease typically requires breeding, aging, and sacrificing hundreds of transgenic rodents over multi-year timelines.
- **The Paradigm Shift:** Academic research groups utilised patient-derived cortical organoids harbouring specific familial Alzheimer’s mutations to evaluate the drug's efficacy and mechanism of action, completely removing animal cohorts from the discovery pipeline.
- **The Methodology:** Computational models were first used to optimize the small molecule's docking profile. The compound was then applied directly to 3D human brain organoids over a 12-week timeline. Researchers successfully quantified reduced tau phosphorylation, restored synaptic vesicle trafficking, and preserved neuronal viability using high-resolution imaging and multi-omics analysis.
- **University & Legal Takeaway:** Demonstrates that high-fidelity human *in vitro* organoid models can serve as primary efficacy screens, providing solid legal justification to the Home Office that animal testing was completely unnecessary for this mechanistic validation pipeline.

Executive Summary & Compliance Dashboard

Executive Summary

Traditional neurobiology workflows rely heavily on legacy *in vivo* models—such as transgenic rodent models and non-human primates—which suffer from severe translational limitations due to species-specific differences in glial phenotypes, neuroinflammatory pathways, and blood-brain barrier (BBB) architecture. This roadmap outlines a transition to high-fidelity, human-relevant NAMs (microfluidic BBB chips, patient-derived brain organoids, and predictive computational networks), moving toward a research paradigm that is more accurate, ethically sound, and fully aligned with the ASPA 1986 mandate to transition away from regulated animal procedures.

Compliance Dashboard

Focus Area	Primary Animal Model	NAM Replacement Technology	ASPA 1986 Status
Neurological / CNS	Transgenic rodent / Non-human primate	BBB-on-chip & Brain organoids	High

See Appendix: Animal-Free Matrix for the long term strategic implementation roadmap

Maturity Matrix

Phase 1 (Exploratory): Audit current animal use in neurodegenerative and cognitive studies.

Phase 2 (Pilot): Integrate brain organoid culture and BBB-on-chip protocols into research pipelines.

Phase 3 (Integration): Implement complex, multi-cellular neuro-immune MPS to model progressive neuroinflammation.

Phase 4 (Standardisation): Replace 100% of high-severity stereotactic and chronic neurodegeneration animal models with qualified human-relevant NAMs.

Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of ASPA 1986. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the fundamental neurological and CNS models explored in this series to the broader immunological and infectious disease frameworks established previously—demonstrate that replacement is not a siloed scientific exercise but an integrated institutional strategy. By mapping these specialised NAM-based neurological platforms into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the ASPA 1986 statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.

Appendix: Animal-Free Maturity Matrix

Neurological & Psychiatric Research Roadmap

This matrix maps the progression of neurological and psychiatric research platforms from legacy *in vivo* reliance to human-relevant, animal-free methodologies.

Technology Platform	Phase 1: Exploration	Phase 2: Integration	Phase 3: Validation	Phase 4: Adoption
Brain Organoids	Proof-of-concept; structural mimicry.	Standardised SOP development.	Multi-lab validation; disease modeling.	Regulatory-standardized use.
NVU-on-a-Chip	Microfluidic architecture design.	Functional BBB permeability testing.	Integration into WoE frameworks.	High-throughput drug screening.
In Silico Twins	Computational circuit design.	AI-driven protein folding analysis.	Predictive longitudinal modeling.	Primary tool for target discovery.
AI Structural Models	Molecule interaction modelling.	Kinetic signalling simulations.	Data benchmarking vs. legacy models.	Core standard for efficacy testing.

Implementation & Compliance Framework

ASPA 1986 Compliance: This roadmap supports the institutional duty to adhere to the principles of the Animals (Scientific Procedures) Act 1986 (ASPA). By prioritizing the principle of replacement, the framework ensures that wherever a scientifically satisfactory non-animal method is available, it must be used instead of a regulated procedure. The goal is to shift from reliance on legacy models to predictive, human-specific safety profiles.

Weight-of-Evidence (WoE) Dossier: To justify the reduction or cessation of non-human primate or rodent studies, researchers must aggregate data from multi-organ kinetic simulations and epitope-mapping outputs to build a robust scientific case.

Regulatory Alignment: The use of advanced platforms—specifically the Lymph Node-on-Chip and Air-Liquid Interface (ALI) models—is intended to align with the expectations of the Animals in Science Regulation Unit (ASRU) and the Home Office for "fit-for-purpose" safety profiling.

Strategic Note: This roadmap is a living instrument. Teams should utilize the "Compliance Dashboard" to track progress against these milestones, ensuring the institution maintains a future-proof, human-relevant research infrastructure.